

TERARECON RECEIVES THE 2023 COMPANY OF THE YEAR AWARD

*Identified as best in class in the global AI-based
neurological solutions industry*

Best Practices Criteria for World-Class Performance

Frost & Sullivan applies a rigorous analytical process to evaluate multiple nominees for each award category before determining the final award recipient. The process involves a detailed evaluation of best practices criteria across two dimensions for each nominated company. TeraRecon excels in many of the criteria in the AI-based neurological solutions space.

AWARD CRITERIA	
<i>Visionary Innovation & Performance</i>	<i>Customer Impact</i>
Addressing Unmet Needs	Price/Performance Value
Visionary Scenarios Through Mega Trends	Customer Purchase Experience
Implementation of Best Practices	Customer Ownership Experience
Leadership Focus	Customer Service Experience
Financial Performance	Brand Equity

Offers AI-based Platforms for Healthcare Facilities

Founded in 1997, US-based TeraRecon operates in over 74 countries and offers AI-empowered solutions

“Advanced AI-based solutions of TeraRecon assist in the rapid management and accurate diagnosis of neurovascular patients. Additionally, its solutions are clinician-friendly and provide informed decision-making and on-the-go view options.”

– Utkarsha Soundankar
Senior Research Analyst

for radiology, oncology, cardiology, musculo-skeletal and neurology. The company has 5,376 active installations, 52,000+ active client software access points, and more than 900 global customers. Over 1,900 health sites trust TeraRecon’s solutions, demonstrating its brand equity.¹ TeraRecon also offers Intuition, an advanced visualization imaging solution; Eureka Clinical AI, an AI-based platform for coordinated care; TR Neuro, and Neuro Suite, AI-based solutions for neurovascular diseases. Its vendor-

neutral solutions provide simplified workflows and actionable insights.

The company has ample industry experience as it first entered the imaging industry and transitioned to advanced imaging and AI-based solutions based on customer needs. Through its Neuro suite, TeraRecon effectively solves multiple challenges, such as delays in diagnosis and lack of care team collaboration in

¹ <https://www.terarecon.com/about>

neurological disease management. The Neuro suite is a comprehensive vendor-neutral solution that aids in neuroimaging analysis and interpretation of treatment decisions. Frost & Sullivan finds TeraRecon embodies the leadership focus criterion by covering a broad range of diseases, including stroke, brain tumors, multiple sclerosis, dementia, Alzheimer's, epilepsy, neurovascular diseases, Moyamoya disease, intracranial stenosis, cerebral small vessel disease, traumatic brain injury, subarachnoid intracranial hemorrhage, and vasospasm. TeraRecon's Neuro suite has the potential to solve multiple AI-based neurological needs in a single platform. Frost & Sullivan commends TeraRecon for its exhaustive and advanced AI-based neurological platform.

Provides a Fast and Accurate Diagnosis Solution

Delays in diagnosing neurological diseases such as stroke are one of the major industry challenges, resulting in long-term disabilities and, in many instances, even death. There is a common saying in neurological diseases—Time is Brain—which means the duration the brain does not get oxygen determines the extent of the damage; the lesser the time, the lesser the damage. Solutions that can rapidly diagnose neurological diseases and reduce door-to-needle time are vital.

Frost & Sullivan's analysis indicates that TR Neuro solves time-related challenges in neurological care. TR Neuro is an AI-based clinical workflow solution that can be deployed on premise, in the cloud or hybrid and provides disease screening and patient care activation in neurovascular emergencies. It generates large vessel occlusion (LVO), intracerebral hemorrhage (ICH), and Alberta Stroke Program Early CT Score (ASPECTS) algorithms to give a complete picture of the patient. TR Neuro also covers auto-generated computerized tomography (CT) perfusion maps. Integrable into the healthcare organization, the solution offers support for emergencies such as stroke and increases the readiness of neurological emergency care centers.

The TR Neuro solution provides an automated screening of ICH and LVO and automated CT perfusion maps. Validated at 40 academic centers in the United States, the LVO algorithm in TR Neuro has 97.7% accuracy, 97.9% sensitivity, and 97.6% specificity. Forty-four institutes in the United States have validated the ICH algorithm in TR Neuro, which has 94% accuracy, 91.4% sensitivity, and 97.5% specificity. The automated CT perfusion maps assist in reducing the analysis time and improving triage. TR Neuro offers seven customizable perfusion maps, including cerebral blood flow (CBF), cerebral blood volume (CBV), time to Peak (TTP), mean transit time (MTT), Tmax, mismatch, and hypo-perfusion.

Users can view TR Neuro using a desktop viewer and mobile application. The desktop web-based application has all the standard picture archiving and communication systems features. It offers AI-based features such as accept/reject, agree/disagree, re-run, re-locate, and worklist optimization. Supported by iOS and Android devices, the mobile application enables physicians to leverage TeraRecon's patented ability to interact directly with the AI and agree or disagree with diagnostic insights using standard finger gestures, keeping physicians in charge of the final patient record.

Clinicians can track different metrics, such as user availability, platform resource utilization, algorithm frequency, and AI success rate reports, by incorporating TeraRecon Analytics in their TR Neuro. It also provides notification of alerts via HL7 communication protocol and e-mail, which offers optimization and prioritization for radiologists. Advanced AI-based solutions of TeraRecon assist in the rapid management

"TeraRecon's Neuro suite ensures increased productivity, consistency, reproducibility, and easy result communication; and offers dedicated tools for neurological disorders. TeraRecon's solutions solve challenges across the care continuum to provide advanced patient care, increase patient outcomes, and reduce the financial burden of neurological diseases."

– Utkarsha Soundankar
Senior Research Analyst

workflow, maintains standardization across the care continuum, and provides timely and coordinated care in neurological settings. TR Neuro offers Health Insurance Portability and Accountability Act-compliant communication tools, such as instant messaging, group chat, and patient-level chat, in the app to enhance care team communication and collaboration.

Offers Clinician-centric Solutions

TR Neuro is a physician-controlled, end-to-end AI experience that enables clinicians to interact with the AI algorithm to improve AI outputs. TeraRecon incorporates its solutions into existing technologies, including desktop and mobile devices. It works alongside or with physicians' current systems, permitting acceptance or rejection of AI outputs and re-running AI-based algorithms. These patented accept, reject, and re-run capabilities ensure physicians are in charge of diagnostic reports, eliminating problems that hinder adoption, such as interference with clinicians' preferences and judgment.

TeraRecon also offers the Premier Success Solution, which provides collaborative and responsive customer services. Premier Success Solution includes personalized assistance for installation, management, updating, and subscriptions of TeraRecon solutions. This solution enables TeraRecon to offer exceptional service and continuous customized customer support.

Delivers a One-stop AI Platform

TeraRecon's Eureka Clinical AI platform supports TeraRecon, third-party, and customer-developed AI algorithms. It is an AI software-as-a-service imaging interpretation and clinical decision-providing platform. This enables combining workflows and tailoring multi-AI model workflows depending on the healthcare facility workflow. Using this platform, care teams in various specialties can see results and receive mobile alerts for confirming findings, thereby providing timely patient care.

TeraRecon partners with different vendors to provide precise, AI-supported patient care and expand in the neurological solutions market and other disease areas. The company partnered with Combinostics in April 2023 to include an AI-based solution in its Eureka Clinical AI platform to enable automated brain magnetic resonance imaging (MRI) quantification, early detection, differential diagnosis, and monitoring

and accurate diagnosis of neurovascular patients. Additionally, its solutions are clinician-friendly and provide informed decision-making and on-the-go view options.

Enables Collaborative Care

Lack of collaboration in the care continuum is a major challenge that delays care for neurovascular diseases such as stroke. TR Neuro's best-in-class solution is accomplished through workflow customization present in the platform as opposed to competitive solutions which were mostly custom made monolithic applications. TR Neuro connects the care team

of neurological disorders. In the same month, TeraRecon partnered with Cercare Medical, a provider of perfusion software to enhance MR and CT imaging.

Its partnership with Combinostics and Imaging Biometrics also allows the TR Neuro suite to offer various advanced features. Combinostics provides rapid, accurate, and early neurological disease diagnosis. It offers objective quantification of abnormalities, patterns, and changes in brain lesions and volume that are difficult to detect; and dedicated reporting and visualization tools for various neurological disorders. Imaging Biometrics provides technology to complement MRI and information to complement anatomical imaging. Through this partnership, TeraRecon offers multiple solutions for diagnosing and managing neurological diseases, including IB Neuro, IB DCE, IB Delta Suite, and IB Diffusion.

TeraRecon also has partnerships to incorporate the Eureka Clinical AI platform with companies such as Bot Image, Inc. for prostate cancer, Radiobotics for osteoarthritis and fracture, Coreline Soft for oncology, Riverain Technologies for chest imaging, InferVision for pulmonary node detection through CT scan, Us2.ai for transthoracic echocardiograms, Avicenna.AI for incidental pulmonary embolism, ClariPi Inc. for lung and breast tissue abnormalities, and CoLumbo for lumbar spine MR scans.

Demonstrates Exceptional Commitment to Providing Advanced and Secure AI-based Solutions

With a solid commitment to innovation, TeraRecon constantly updates and provides enhanced versions to customers. The company updated its Eureka Clinical AI platform in May 2023 to provide advanced features such as sequential AI analysis after its re-launch in October 2022. TeraRecon's AI platform enables hosting all AI algorithms, including those developed by TeraRecon, customers, and third parties. In addition, the platform is physician-centric, offers easy integration into hospital systems, and acts as a single point of contact for all AI solutions. TeraRecon provides solutions that are transparent, scalable, robust, and secure. Its excellent solutions allowed TeraRecon to receive the Category Leader award for 2020, 2021, and 2022 KLAS Advanced Visualization.

TeraRecon focuses on securing patient data and providing advanced cybersecurity. This commitment enabled TeraRecon to receive recognition as an International Organization for Standardization (ISO) 27001:2022 company in May 2023. The certification ensures that the company prioritizes patient data security and invests in information security infrastructure. With its advanced AI-based secure solutions, TeraRecon continuously meets customer needs and increases patient outcomes.

Frost & Sullivan firmly believes that TeraRecon demonstrates high growth potential and is well-positioned to improve the AI-based neurological solutions industry.

Conclusion

TeraRecon offers workflow-driven and physician-centric solutions through its TR Neuro and Neuro Suite that significantly increase collaboration and diagnosis time in neurological disease areas. These solutions ensure increased productivity, consistency, reproducibility, and easy result communication; and offers dedicated tools for neurological disorders. TeraRecon's solutions solve challenges across the care continuum to provide advanced patient care, increase patient outcomes, and reduce the financial burden of neurological diseases.

For its strong overall performance, TeraRecon earns Frost & Sullivan's 2023 Global Company of the Year Award in the AI-based neurological solutions industry.

What You Need to Know about the Company of the Year Recognition

Frost & Sullivan's Company of the Year Award is its top honor and recognizes the market participant that exemplifies visionary innovation, market-leading performance, and unmatched customer care.

Best Practices Award Analysis

For the Company of the Year Award, Frost & Sullivan analysts independently evaluated the criteria listed below.

Visionary Innovation & Performance

Addressing Unmet Needs: Customers' unmet or under-served needs are unearthed and addressed by a robust solution development process

Visionary Scenarios Through Mega Trends: Long-range, macro-level scenarios are incorporated into the innovation strategy through the use of Mega Trends, thereby enabling first-to-market solutions and new growth opportunities

Leadership Focus: Company focuses on building a leadership position in core markets and on creating stiff barriers to entry for new competitors

Best Practices Implementation: Best-in-class implementation is characterized by processes, tools, or activities that generate a consistent and repeatable level of success

Financial Performance: Strong overall business performance is achieved in terms of revenue, revenue growth, operating margin, and other key financial metrics

Customer Impact

Price/Performance Value: Products or services provide the best value for the price compared to similar market offerings

Customer Purchase Experience: Quality of the purchase experience assures customers that they are buying the optimal solution for addressing their unique needs and constraints

Customer Ownership Experience: Customers proudly own the company's product or service and have a positive experience throughout the life of the product or service

Customer Service Experience: Customer service is accessible, fast, stress-free, and high quality

Brand Equity: Customers perceive the brand positively and exhibit high brand loyalty

About Frost & Sullivan

Frost & Sullivan is the Growth Pipeline Company™. We power our clients to a future shaped by growth. Our Growth Pipeline as a Service™ provides the CEO and the CEO's growth team with a continuous and rigorous platform of growth opportunities, ensuring long-term success. To achieve positive outcomes, our team leverages over 60 years of experience, coaching organizations of all types and sizes across 6 continents with our proven best practices. To power your Growth Pipeline future, visit Frost & Sullivan at <http://www.frost.com>.

The Growth Pipeline Engine™

Frost & Sullivan’s proprietary model to systematically create ongoing growth opportunities and strategies for our clients is fuelled by the Innovation Generator™.

[Learn more.](#)

Key Impacts:

- **Growth Pipeline:** Continuous Flow of Growth Opportunities
- **Growth Strategies:** Proven Best Practices
- **Innovation Culture:** Optimized Customer Experience
- **ROI & Margin:** Implementation Excellence
- **Transformational Growth:** Industry Leadership



The Innovation Generator™

Our 6 analytical perspectives are crucial in capturing the broadest range of innovative growth opportunities, most of which occur at the points of these perspectives.

Analytical Perspectives:

- **Mega Trend (MT)**
- **Business Model (BM)**
- **Technology (TE)**
- **Industries (IN)**
- **Customer (CU)**
- **Geographies (GE)**

